Filing Flows › Gyre Therapeutics (GYRE) › Q3 2026 › vs Q2 2026
Gyre Therapeutics (GYRE) Q3 2026 vs Q2 2026 (quarter over quarter)
Gyre Therapeutics's revenue rose $3.8M (+13%) from $29.1M in Q2 2026 to $32.9M in Q3 2026. The biggest changes: Gyre Pharmaceuticals +$3.3M (+11%); Gyre +$500K (64×).
Gyre Therapeutics, Q3 2026: revenue $32.9M (+0.7% year over year), operating margin -4.6%, net loss $2.5M, operating cash flow −$4.0M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Gyre Pharmaceuticals | $32.4M | $29.1M | $3.3M | +11% |
| Gyre | $508K | $8K | $500K | 64× |
| Revenue | $32.9M | $29.1M | $3.8M | +13% |
| Net loss | $2.5M | $23.0M | −$20.5M | -89% |
| Costs & expenses | $35.4M | $52.3M | −$16.8M | -32% |
| Operating costs | $34.5M | $43.5M | −$9.0M | -21% |
| Interest & other, net | $225K | $8.8M | −$8.6M | -97% |
| Income tax | $733K | −$164K | $897K | — |
| Cost of revenue | $1.9M | $2.2M | −$262K | -12% |
| SG&A | $8.9M | $7.9M | $1.1M | +14% |
| Other operating costs | $23.6M | $33.4M | −$9.8M | -29% |
| Operating cash sources | $6.2M | $20.3M | −$14.1M | -70% |
| Depreciation & amortization | $467K | $1.5M | −$1.0M | -69% |
| Share-based compensation | $1.7M | $2.1M | −$341K | -16% |
| Cash used in operations | $4.0M | $16.7M | −$12.7M | -76% |
| Net loss absorbed | $2.5M | $23.0M | −$20.5M | -89% |
| Working capital & other | $3.7M | −$2.7M | $6.4M | — |
Questions
How much did Gyre Therapeutics's revenue grow quarter over quarter in Q3 2026?
Gyre Therapeutics's revenue rose $3.8M (+13%) from $29.1M in Q2 2026 to $32.9M in Q3 2026.
What drove Gyre Therapeutics's revenue change in Q3 2026?
Gyre Pharmaceuticals +$3.3M (+11%); Gyre +$500K (64×).